CytoCore, Inc. Announces New Cancer Screening and Treatment System On The Horizon

CytoCore, Inc. Announces
New Cancer Screening and Treatment System On The Horizon

CHICAGO – CytoCore, Inc., a biomolecular diagnostics screening company committed to bringing new cancer solutions to the market, has announced the development of a new screening and treatment system. CytoCore has developed the InPath™ System, a cervical/uterine cancer screening and treatment system that will provide a rapid-answer and reassurance to women who test negative, and will equip physicians with the ability to advise additional treatment in cases of a positive suspected result.

CytoCore has received approval from the U.S. Food and Drug Administration (FDA) to sell the first of the company’s products from the InPath™ System, the e2 Collector. The e2 Collector is designed to improve the consistency and thoroughness of cell collection for the Pap test, which is currently subject to significant variability based on the physician’s collection technique using the spatula and brush. Unlike the current cell collection method for the Pap test, which involves scraping parts of the cervix to obtain cell samples, the e2 Collector uses a touch method to gather cells on the “sticky” surface of a balloon which is inflated against cervix and into the cervical canal to capture cells from all the at risk surface areas of the cervix. The consistency and improvement of cell collection will provide a significant increase in the accuracy of the Pap test. The e2 Collector is targeted to be ready for initial production and sales by the end of the year. Testing will begin on the additional InPath™ System products in the fall.

About CytoCore, Inc.:
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, and endometrial cancers. The InPath™ System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: http://www.Molecular-Dx.com.

Certain statements in this release are forward-looking. These statements are based on CytoCore’s current expectations and involve many risks and uncertainties, such as the company’s inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore’s expectations with respect to the InPath™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore’s current expectation depending upon a number of factors affecting the Company’s business. These factors include, among others, risks and uncertainties detailed in the Company’s periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contacts:

Patty Briguglio
MMI Associates, Inc.
919-233-6600
patty@mmimarketing.com

Director Communications
Gene Martineau
(212)348-1852
ebm@interport.net